Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT04797442 - Akkermansia muciniphila WST01 vs Placebo & Adiposity / Obesity or Type 2 Diabetes (T2D)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background

Akkermansia muciniphila is a promising target for managing obesity and type 2 diabetes (T2D). However, human studies are limited.
Zhang et al. 2025 Cell Metab 37(3): 592-605

Study overview

NCT04797442 - Akkermansia muciniphila WST01 vs Placebo & Adiposity / Obesity (T2D Patients) is a randomized clinical phase II treatment trial to study Akkermansia muciniphila WST01 or placebo in 58 enrolled participants with overweight or obese Type 2 Diabetes (T2D)
Zhang et al. 2025 Cell Metab 37(3): 592-605

Primary outcome measur…

References (Sources)

Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut
Zhang et al. 2025 Cell Metab 37(3): 592-605
The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives
Vallianou et al. 2023 Int J Mol Sci 24(7) :6755
Review

AI Chat

4/13/2026

Chat with our artificial intelligence:

Start chat!